French Version of the Hayling Sentence Completion Test, Part II: Clinical Utility in Schizophrenia and Parkinson's Disease.
OBJECTIVE
We previously developed normative data for a French version of the Hayling Sentence Completion Test (f-HSCT) for adults and elderly people. The present study aimed to evaluate the clinical utility of the f-HSCT norms in two clinical populations in which inhibition dysfunction has been largely documented, i.e., Parkinson's disease (PD) and schizophrenia.


METHODS
Eighty-five non-demented patients with idiopathic PD and 64 out-patients with schizophrenia completed the automatic and inhibition conditions of the f-HSCT. Time latencies and errors raw data of each patient were compared to the norms previously developed by the authors.


RESULTS
In the automatic condition, errors were rare in both clinical groups and time latencies on this condition felt within the normative data range. Compared with the standardized norms, 46% of patients with PD and 61% of patients with schizophrenia had a deviant performance (i.e., borderline or deficit) for the inhibition error score. The proportion of patients with a deviant performance on the inhibition response time score was similar in both clinical samples (respectively, 25% and 23%). Finally, slightly more than half of patients with PD and more than two-thirds of patients with schizophrenia had a deviant performance on at least one of the f-HSCT inhibition measures.


CONCLUSIONS
Our results suggest that the f-HSCT has a strong potential for characterizing inhibition of prepotent responses in PD and schizophrenia. Furthermore, it requires only a short administration time so it may be ideal to detect response inhibition in clinical populations with cognitive fatigue.
Laboratoire Epsylon, EA 4556 , Université Paul Valéry Montpellier 3, Montpellier, France.
Sophie
S
Bayard
Équipe "Neuropsychologie, Audition, Cognition, Action" (NACA), Laboratoire "Psychologie: Interactions, Temps, Emotions, Cognition" (PSITEC) EA 4072, Université Lille Nord de France, France.
Christine
C
Moroni
Laboratoire Epsylon, EA 4556 , Université Paul Valéry Montpellier 3, Montpellier, France.
Marie-Christine
MC
Gély-Nargeot
Centre Expert Maladie de Parkinson, Service Universitaire de Neurologie, CHRU Montpellier, Montpellier , France.
Alexia
A
Rossignol-Arifi
Centre de Gérontologie, Hôpital de Martigues, France.
Emmanuelle
E
Kamara
Laboratoire Epsylon, EA 4556, Université Paul Valéry Montpellier 3, Montpellier, France.|Service Universitaire de Psychiatrie Adulte, CHRU Montpellier, Montpellier, France.
Stéphane
S
Raffard
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D060825:Cognitive Dysfunction / Q000175:diagnosis* / Q000209:etiology*; D056344:Executive Function / Q000502:physiology*; D005260:Female; D006801:Humans; D007266:Inhibition, Psychological; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests / Q000592:standards*; D010300:Parkinson Disease / Q000150:complications*; D011237:Predictive Value of Tests; D012559:Schizophrenia / Q000150:complications*; D055815:Young Adult
Hayling Sentence Completion Test; Inhibition; Parkinson's disease executive functions; Schizophrenia